Biological Response Modifiers

Report Highlights

• The overall BRM market is projected to have an average annual growth rate (AAGR) of about 13% through 2007, reaching nearly $30 billion.
• There are more than two-dozen BRMs on the market and more than 20 new products/new indications in Phase III or later development.
• Erythropoietin held about 52% the market in 2001.
• Tumor necrosis factors and interleukins are projected to experience an AAGR in excess of 20%.

INTRODUCTION

Biological response modifiers (BRMs), also referred to as cytokines, comprise a group of products that are intrinsic to the body and alter immune defenses to enhance, direct or restore the body's ability to fight disease. Biological response modifiers included in this report are: colony stimulating factors (CSFs), erythropoietins, interferons, interleukins (ILs) and tumor necrosis factor (TNF) inhibitors.

This timely and comprehensive report provides a range of information, from detailed market analyses through industry trends, that quantifies and qualifies the market for BRMs. It analyzes and assesses the BRM market by product and category for the period 2001 through 2007, and discusses products in Phase II or later development by disease application. Technology issues and breakthroughs, as well as industry trends, also are discussed. The study presents biotechnology and pharmaceutical company profiles, and examines the strategies employed by these firms to develop and market products in this rapidly expanding market sector. It also looks at companies developing innovative products not yet launched.

The report provides an important analysis of current markets for BRMs and, in particular, the market potential of promising drugs and technologies under development. It is, therefore, invaluable in decision making for CEOs, presidents and managers involved in development, marketing, strategic planning, market research, product development, mergers and acquisitions, licensing, investment banking and deal creation, as well as for consultants to the pharmaceutical and biotechnology industry.

SCOPE OF STUDY

This report covers:

• Definitions of the types of BRMs and their effects on the immune system
• The market and trends of available and emerging BRMs
• Leading indications in development for anemia and bone marrow/stem cell transplantation, cancer and infectious diseases, inflammatory diseases and multiple sclerosis
• Synopsis of products, and sales analyses of all the leading BRM drugs
• Worldwide market size and growth estimates for the BRM drug categories
• The market potential of generic biologic products including the leading BRMs
• Company profiles.

METHODOLOGY

The base year for this study is 2002. Figures are based on revenue Figures at the manufacturers' level and are projected at 2002 dollar values. Inflation is not computed into the projection Figures.

Information to prepare this study was derived from information obtained from product managers, marketing strategists, research executives, and others at leading pharmaceutical and biotechnology companies that compete in the market for BRM drugs or which have products in development for this market.

INFORMATION SOURCES

The information and analysis presented in this report are based on an extensive survey of the biotechnology and pharmaceutical industries as well as a detailed examination of published literature and reports obtained from regulatory authorities, medical research institutions, pharmaceutical trade associations, and national and world health organizations. Key information from the literature was used to obtain expert opinion on commercial potential and market sizes from industry professionals.